Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from Nasdaq

Benzinga's Top Ratings Upgrades, Downgrades For May 19, 2022

Upgrades

Benzinga

5 Analysts Have This to Say About GDS Holdings

GDS Holdings (NASDAQ:GDS) has observed the following analyst ratings within the last quarter:

Benzinga

Analog Devices's Return on Invested Capital Overview

According to Benzinga Pro, during Q2, Analog Devices (NASDAQ:ADI) earned $783.27 million, a 179.66% increase from the preceding quarter. Analog Devices also posted a total of $2.97 billion in sales, a 10.73% increase since Q1.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Horizon Therapeutics Earnings Perspective: Return On Capital Employed

According to Benzinga Pro, during Q1, Horizon Therapeutics (NASDAQ:HZNP) earned $204.26 million, a 17.95% increase from the preceding quarter. Horizon Therapeutics's sales decreased to $885.25 million, a 12.7% change since Q4.

Benzinga

Seres Therapeutics Earnings Perspective: Return On Capital Employed

Benzinga Pro data, Seres Therapeutics (NASDAQ:MCRB) reported Q1 sales of $1.49 million. Earnings fell to a loss of $56.62 million, resulting in a 13.25% decrease from last quarter.

Benzinga

Editas Medicine's Return On Capital Employed Insights

Benzinga Pro data, Editas Medicine (NASDAQ:EDIT) reported Q1 sales of $6.77 million. Earnings fell to a loss of $50.52 million, resulting in a 21.91% decrease from last quarter.

Benzinga

Gentherm Earnings Perspective: Return On Invested Capital

According to Benzinga Pro data Gentherm (NASDAQ:THRM) posted a 41.41% decrease in earnings from Q4. Sales, however, increased by 7.83% over the previous quarter to $267.66 million.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Wingstop's Return On Capital Employed Insights

According to Benzinga Pro, during Q1, Wingstop (NASDAQ:WING) earned $8.68 million, a 25.81% increase from the preceding quarter. Wingstop also posted a total of $76.20 million in sales, a 5.8% increase since Q4.

Benzinga

Gibraltar Industries Earnings Perspective: Return On Capital Employed

According to Benzinga Pro, during Q1, Gibraltar Industries (NASDAQ:ROCK) earned $15.46 million, a 65.09% increase from the preceding quarter. Gibraltar Industries's sales decreased to $317.87 million, a 4.96% change since Q4.

Benzinga

As Nvidia Stock Slides, Here's How To Play The Counter-Trend

NVIDIA Corporation (NASDAQ: NVDA) plunged over 6% during Wednesday’s trading session in sympathy with the S&P 500, which shed 4%.

Benzinga

Expert Ratings for Argo Blockchain

Within the last quarter, Argo Blockchain (NASDAQ:ARBK) has observed the following analyst ratings:

Benzinga

Replimune Group: Q4 Earnings Insights

Replimune Group (NASDAQ:REPL) reported its Q4 earnings results on Thursday, May 19, 2022 at 08:00 AM. Here's what investors need to know about the announcement. Earnings Replimune Group missed estimated earnings by 3.45%, reporting an EPS of $-0.6 versus an estimate of $-0.58.

Benzinga

Expert Ratings for Aptinyx

Within the last quarter, Aptinyx (NASDAQ:APTX) has observed the following analyst ratings:

Benzinga

Executives Buy Around $17M Of 5 Penny Stocks

The Nasdaq Composite index tumbled by more than 550 points on Wednesday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their…

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Why Cisco Systems Stock Is Falling Today

Cisco Systems Inc (NASDAQ: CSCO) shares are trading lower Thursday after the company reported worse-than-expected top-line results and issued guidance below analyst estimates.

Benzinga

Morning Brief: Top Financial Stories Dominating on Thursday, May 19

CNBC CDC Looking Into 180 Cases Of Unexplained Pediatric Acute Hepatitis

Benzinga

10 Biggest Price Target Changes For Thursday

Telsey Advisory Group cut the price target for Bath & Body Works, Inc. (NYSE: BBWI) from $70 to $60. Bath & Body Works shares fell 6.9% to $40.00 in pre-market trading.

Benzinga

Recap: Nano X Imaging Q1 Earnings

Nano X Imaging (NASDAQ:NNOX) reported its Q1 earnings results on Thursday, May 19, 2022 at 07:30 AM. Here's what investors need to know about the announcement.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Children's Place: Q1 Earnings Insights

Children's Place (NASDAQ:PLCE) reported its Q1 earnings results on Thursday, May 19, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Benzinga

Cannabis Movers & Shakers: Flora Growth, Valens, Metrc, Treez

Flora Growth Welcomes Cannabis Regulatory Veteran Holly Bell As VP Of Regulatory Affairs Flora Growth Corp. (NASDAQ: FLGC) has tapped regulatory veteran Holly Bell to serve as vice president of regulatory affairs.

Benzinga

HubSpot And 2 Other Stocks Insiders Are Buying

Although the Dow Jones dipped sharply by over 1,150 points on Wednesday, there were a few notable insider trades.

Benzinga

Why Cathie Wood Says Record-Breaking Inventories Could Lead To Weaker Prices

Benzinga

Mersana Stock Gains On FDA Orphan Drug Designation For Gastric Cancer Drug

Mersana Therapeutics, Inc. (NASDAQ: MRSN) received orphan drug designation from the U.S. Food and Drug Administration (FDA) for its drug candidate XMT-2056 or the treatment of gastric cancer. The company is planning to start a clinical study evaluating XMT-2056 for gastric and other cancers.

Benzinga

The Daily Biotech Pulse: Valneva's COVID-19 Vaccine Filing Accepted By EMA, Enanta's RSV Candidate Fails, Orphan Drug Tag For Mersana's Gastric Cancer Candidate

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

G Medical Warns On Missing Q1 Sales Guidance Of $30M

G Medical Innovations Holdings Ltd (NASDAQ:GMVD) said that it would not meet its forecast of $30 million in revenues in Q1 of 2022. The company said that the previously reported purchase orders from McDade Products LLC for 6 million co-branded LiveNow COVID-19 PCR Test Collection Kits (approximately $20 million in orders) have not materialized into…

1 … 510 511 512 513

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

University of Michigan

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.